Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,273 | 260 | 996 |
| Samples | 625 | 161 | 455 |
| Peptides | 456 | 98 | 375 |
Function
ZP4 · Zona pellucida glycoprotein 4
The zona pellucida is an extracellular matrix that surrounds the oocyte and early embryo. It is composed primarily of three or four glycoproteins with various functions during fertilization and preimplantation development. The nascent protein contains a N-terminal signal peptide sequence, a conserved ZP domain, a consensus furin cleavage site, and a C-terminal transmembrane domain. It is hypothesized that furin cleavage results in release of the mature protein from the plasma membrane for subsequent incorporation into the zona pellucida matrix. However, the requirement for furin cleavage in this process remains controversial based on mouse studies. Previously, this gene has been referred to as ZP1 or ZPB and thought to have similar functions as mouse Zp1. However, a human gene with higher similarity and chromosomal synteny to mouse Zp1 has been assigned the symbol ZP1 and this gene has been assigned the symbol ZP4. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 452 amino-acid changes on canonical ENST00000366570 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ZP4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ZP4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Non-Small Cell Lung Carcinoma | 52/304 17% | 72/1390 5% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 27/810 3% |
| Melanoma | 13/210 6% | 59/1899 3% |
| Endometrial Carcinoma | 4/42 10% | 18/612 3% |
| Neuroendocrine Tumour | 14/154 9% | 7/577 1% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 19/752 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Gastric Carcinoma | 5/74 7% | 26/1809 1% |
| Colorectal Carcinoma | 8/143 6% | 47/3239 1% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Plasma Cell Myeloma | 3/44 7% | 2/305 1% |
| Other Sarcomas | 3/69 4% | 7/699 1% |
| Non-Cancerous | 1/104 1% | 9/830 1% |
| Other Solid Cancers | 0/94 0% | 17/1515 1% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Biliary Tract Carcinoma | 4/54 7% | 6/950 1% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Hepatocellular Carcinoma | 1/46 2% | 19/2210 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| B-Cell Non-Hodgkins Lymphoma | 9/88 10% | 13/2534 1% |
| Bladder Carcinoma | 1/58 2% | 7/956 1% |
| Breast Carcinoma | 3/144 2% | 21/3264 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 9/1592 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
Mutation Distribution
Where ZP4 is mutated · all tissues, split by cell line vs tissue
How many mutations in ZP4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 1 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,273 mutations in ZP4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|